Bradley Schroeder
Gastroenterology · Omaha, NENPI 1407821333
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 378 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 26.1% of the total. Reporting peaked in 2023 at $1,756 and has fallen 98.0% since, to $36 in 2024.
Across 378 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$831
- Johnson & Johnson$722
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$701
- QOL Medical, LLC$313
- Gilead$281
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,78799%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,520 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $831 |
| Johnson & Johnson | 61 | $722 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $701 |
| QOL Medical, LLC | 21 | $313 |
| Gilead | 17 | $281 |
| Nestle Healthcare Nutrition Inc. | 2 | $203 |
| Sanofi | 8 | $183 |
| Regeneron Healthcare Solutions, Inc. | 9 | $157 |
| Amgen | 7 | $128 |
| Ironwood Pharmaceuticals, Inc | 8 | $120 |
| Bristol Myers Squibb | 7 | $114 |
| Pfizer | 6 | $77 |
| Ardelyx, Inc. | 4 | $74 |
| Merck | 4 | $70 |
| Organon | 4 | $60 |
| Intercept Pharmaceuticals, Inc. | 4 | $55 |
| UCB, Inc. | 4 | $54 |
| Boehringer Ingelheim | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Welch Allyn | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOWST$190
How this compares
$5,817 in reported general payments places this provider in the 70th percentile of 89 gastroenterology providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colestipol Hcl | 19 | $3,272 |
| Mesalamine ErMesalamine | 22 | $2,646 |
| Memantine Hcl | 12 | $1,977 |
| Omeprazole | 112 | $1,596 |
| Pantoprazole Sodium | 67 | $1,068 |
| Olmesartan Medoxomil | 12 | $928 |
| Famotidine | 43 | $503 |
| Sucralfate | 12 | $447 |
| Levothyroxine Sodium | 11 | $152 |
| Atenolol | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.